Bristol-Myers Squibb Company (BMY) Competitors & Peers
The 5 largest companies in the same industry as Bristol-Myers Squibb Company, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Peer | $1,354.00 | P/E 44.0RSI 61Cap 1.28 T |
| JNJ | Peer | $276.22 | P/E 41.9RSI 59Cap 664.9 B |
| ABBV | Peer | $291.31 | P/E 50.0RSI 60Cap 514.7 B |
| MRK | Competitor | $146.73 | P/E 148.2RSI 51Cap 362.4 B |
| AZN | Peer | $186.43 | P/E 26.4RSI 69Cap 289.1 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- MRKCompetitor
Bristol-Myers Squibb (Opdivo) and Merck (Keytruda) are the two dominant competitors in PD-1/PD-L1 checkpoint inhibitor oncology.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CLDXSupplier
Own 10-K customer-concentration disclosure: BristolMeyersSquibbCompany = 31% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CORSupplier
Cencora is Bristol-Myers Squibb's second-largest wholesale distributor, accounting for approximately 19% of gross revenues in FY2025.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CAHSupplier
Cardinal Health is Bristol-Myers Squibb's third-largest wholesale distributor, accounting for approximately 13% of gross revenues in FY2025.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MCKSupplier
McKesson is Bristol-Myers Squibb's largest wholesale distributor, accounting for approximately 42% of gross revenues in FY2025.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- MRTXPartner
BMY acquired Mirati $4.8B closed Jan 2024.
Model-inferred, unverified — treat as a lead, not evidence - PFEPartner
Pfizer and BMS co-develop and co-commercialize Eliquis (apixaban) globally — one of the most valuable pharmaceutical co-promotion arrangements in history.
Model-inferred, unverified — treat as a lead, not evidence - MRTXMerger
BMY acquired Mirati $4.8B closed Jan 2024.
Model-inferred, unverified — treat as a lead, not evidence - REPLPartner
Collaborates on clinical combination trials pairing Replimune's RP1 with BMS's Opdivo (nivolumab).
Model-inferred, unverified — treat as a lead, not evidence - NKTRPartner
Nektar co-develops oncology candidate drug therapies with BMS.
Model-inferred, unverified — treat as a lead, not evidence - ALMSCompetitor
Alumis' ESK-001 competes with BMS's approved TYK2 inhibitor Sotyktu.
Model-inferred, unverified — treat as a lead, not evidence - ONCPartner
Bristol Myers BMS partners with BeOne to evaluate oncology combinations.
Model-inferred, unverified — treat as a lead, not evidence